From: Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies
Drug, dose, treatment regimen, and route of administration | Study’s design | Study’s details and outcome measures | Main results | Sex | Age in years | Health status | Cannabis consume | Reference |
---|---|---|---|---|---|---|---|---|
Dronabinol 7.5 mg, acute, 2 h prior to EL, v.o. | Randomized, double-blind, placebo-controlled | Image presentation associated with sound presentation and SCR | ↓ SCR 24 h after EL | ♂ ♀ | 21–45 | Healthy | Non-users | [70] |
Dronabinol 7.5 mg, acute, 2 h prior to EL, v.o. | Randomized, double-blind, placebo-controlled, | fMRI scanning, resting-state functional connectivity analysis, and SCR | ↑ vmPFC and hippocampus activation during EMR; ↓ Amygdala activity during early extinction learning; ↔ SCR | ♂ ♀ | 21–45 | Healthy | Non-users | [71] |
Dronabinol 7.5 mg, acute, 2 h prior to EL, v.o. | Randomized, double-blind, placebo-controlled, | fMRI scanning and Resting-state functional connectivity analysis | ↓ Recovery of fear after 24 h; ↓ Amygdala-hippocampus static functional connectivity; ↑ Amygdala-vmPFC dynamic functional connectivity | ♂ ♀ | 21–45 | Healthy | Non-users | [72] |
Dronabinol 7.5 mg, acute, 2 h prior to EL, v.o. | Randomized, double-blind, placebo-controlled, | fMRI scanning and SCR | ↓ vmPFC and amygdala responses and ↑ functional coupling between the vmPFC, hippocampus and dACC 1 week later; ↓ SCR in first extinction trials; ↓ SCR in EMR 24 h later; ↔ 1 week after the EL | ♂ ♀ | 21–45 | Healthy | Non-users | [73] |
Dronabinol 10 mg, acute, 2 h prior to EL, v.o. | Double-blind, placebo-controlled, | FPS and SCR | ↓ SCR during EL ↔ FPS | ♂ ♀ | 18–30 | Healthy | Non-users | [74] |